T cell receptor (on cytotoxic T lymphocyte) (TCR)

The **T cell receptor (TCR)** on cytotoxic T lymphocytes (CTLs; also known as CD8+ T cells) is a membrane-bound heterodimeric protein complex that is essential for the adaptive immune response[2][4][5]. The canonical TCR consists of two chains (usually α and β, or less commonly γ and δ), each comprising variable and constant regions, and associates non-covalently with the CD3 complex (CD3γ, CD3δ, CD3ε, CD3ζ chains) required for signaling[2][4][5]. Upon antigen recognition, the receptor transduces intracellular signals (through ITAM motifs in CD3 chains), activating the CTL to kill the target cell via release of cytolytic granules (containing perforin, granzymes, granulysin) and expression of death ligands (e.g., Fas ligand), as well as by secretion of cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α)[3][5][7]. Dysregulation or inappropriate activation of TCR signaling is implicated in diseases including autoimmune disorders, cancer, and transplant rejection[3][4]. While there are no direct small molecule drugs targeting the TCR itself, its signaling axis is central in immunotherapy (e.g., CAR-T, TCR-T therapies) and immunosuppressive regimens (e.g., inhibitors of calcineurin downstream of TCR activation)[4][5]. Safety challenges of targeting the TCR system arise from the potential for severe immune activation, off-target effects, and autoimmunity. TCR sequence diversity, clonality, and repertoire may be used as biomarkers in immune monitoring and response to immunotherapy. The TCR is a foundational element of adaptive immunity and a prototypical receptor superfamily member responsible for cellular immune surveillance and killing of infected and malignant cells[2][3][4][5][7].

Other names

TCRT cell antigen receptorαβ T cell receptorT cell receptor complexCD3–TCR complex

Antigen-specific activation: Drugs/biologics may introduce tumor or viral antigens recognized by TCR on cytotoxic T cells, leading to targeted killing. Immunosuppression: Some immunosuppressants inhibit downstream TCR signal transduction (e.g., calcineurin inhibitors).